Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-09-12
1992-09-08
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31415
Patent
active
051458624
ABSTRACT:
A method of resisting neurological damage caused by overstimulation of the NMDA receptor of nerve cells by glutamate includes exposing the NMDA receptors to an oxidizing agent to thereby diminish overall activity of the receptors following activation by glutamate. The oxidizing agent preferably is a material selected from the group consisting of pyrroloquinoline quinone and topa hydantoin.
REFERENCES:
patent: 4806543 (1989-02-01), Choi
Drejer et al., Journal of Neurochemistry, 45:145-151 (1985) Cellular Origin f Ischemia-Induced Glutamate Release from Brain Tissue In Vivo and In Vitro.
Simon et al., Science 226:850-852 (1984) Blockade of N-Methyl-D-Aspartate Receptors May Protect Against Ischemic Damage in the Brain.
Gill, et al., Neuroscience 7:3343-3349 (1987) Systemic Administration of MK-801 Protects Against Ischemia-Induced Hippocampal Neurodegeneration in the Gerbil.
Andine et al., Neuroscience Letters 90:208-212 (1988) The excitatory a amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection.
Kochhar et al., Arch. Neurol. 45:148-153 (1988) Glutamate Antagonist Therapy Reduces Neurologic Deficits Produced by Focal Central Nervous System Ischemia.
Barnes, Science vol. 239, pp. 254-256 (1988) NMDA Receptors Trigger Excitement.
Hahn et al., Science USA, 85:6556 (1988)-Central mammalian neurons normally nesistant to glutamate toxicity are made sensitive by elevated extracellular CA.sup.2+ : Toxicity is blocked by the N-methyl-D-aspartate antagonist MK-801.
Choi et al., Neuron, 1:623-634 (1988) Glutamate Neurotoxicity and Diseases of the Nervous System.
Choi et al., The Journal of Neuroscience, 7(2):357-368 (1987) Glutamate Neurotoxicity in Cortical Cell Culture.
Choi et al., The Journal of Neuroscience 8(1):185-196 (1988) Pharmacology of Glutamate Neurotoxicity in Cortical Cell Culture:Attenuation by NMDA Antagonists.
Steinberg et al., Stroke 20:1247-1252 (1989) Protective Effect of N-Methyl-D-Aspartate Antagonists After Focal Cerebral Ischemia in Rabbits.
Nowack et al., Nature 307:462-564 (1984) Magnesium gates glutamate-activated channels in mouse central neurones.
Johnson et al., Nature 325:529-531 (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons.
Westbrook et al., Nature 328:640-643 (1987) Micromolar Concentrations of Zn.sup.2+ Antagonize NMDA and GABA Responses of Hippocampal Neurons.
Peters et al., Science 236:589-593 (1987) Zinc Selectively Blocks the Action of N-Methyl-D-Aspartate on Cortical Neurons.
Ranson et al. J. Neurochem. 51:830-836 (1988) Cooperative Modulation of [.sup.3 H]MK-801 Binding to the N-Methyl-D-Aspartate Receptor-Ion Channel Complex by L-Glutamate, Glycine, and Polyamines.
Mayer et al., Tins, pp. 59-61 (1987) Cellular mechanisms underlying excitotoxicity.
Gill et al., Neuroscience, 25:847-855 (1988) KM-801 is Neuroprotective in Gerbils When Administered During the Post-Ischaemic Period.
Tecoma et al., Neuron, 2:1541-1545 (1989) Traumatic Neuronal Injury in Vitro is Attenuated by NMDA Antagonists.
Aizenman et al., Neuron, 2:1257-1263 (1989) Selective Modulation of NMDA Responses by Reduction and Oxidation.
Gallop et al., Trends in Biochemical Sciences 14:343-346 (1989) PQQ, the elusive coenzyme.
Killgore, Science, 245:850-852 (1989) Nutritional Importance of Pyrroloquinoline Quinone.
Rosenberg et al., Neuroscience Letters, 103:162-168 (1989) Hundred-fold Increase in Neuronal Vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral cortex.
Aizeman et al., Neuroscience Letters 116:168-171 (1990) A 3,4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons.
Levy et al., Neuroscience Letters 110:291-296 (1990) Re
The invention described herein was made in the course of work supported in part by Public Health Service, Grant No. DAO4975 from the National Institutes of Health, National Institute on Drug Abuse. The Government has certain rights in this invention.
This is a division of application Ser. No. 568,301, filed Aug. 16, 1990, now U.S. Pat. No. 5,091,391.
Aizenman Elias
Gallop Paul M.
Rosenberg Paul A.
Friedman S. J.
Silverman Arnold B.
University of Pittsburgh of the Commonwealth System of Higher Ed
LandOfFree
Method of resisting neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of resisting neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of resisting neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-134557